HC Wainwright Reiterates $4.00 Price Target for BioDelivery Sciences International, Inc. (BDSI)

HC Wainwright set a $4.00 price objective on BioDelivery Sciences International, Inc. (NASDAQ:BDSI) in a research report released on Monday morning. The firm currently has a buy rating on the specialty pharmaceutical company’s stock.

Several other analysts have also recently commented on the stock. Roth Capital set a $5.00 target price on shares of BioDelivery Sciences International and gave the stock a buy rating in a research note on Tuesday, May 16th. Janney Montgomery Scott raised their target price on shares of BioDelivery Sciences International from $3.00 to $4.00 and gave the stock a fair value rating in a research note on Monday. Cantor Fitzgerald upgraded shares of BioDelivery Sciences International from a neutral rating to an overweight rating and raised their target price for the stock from $3.00 to $4.00 in a research note on Tuesday, May 16th. ValuEngine cut shares of BioDelivery Sciences International from a hold rating to a sell rating in a research note on Friday, June 2nd. Finally, FBR & Co set a $4.00 target price on shares of BioDelivery Sciences International and gave the stock a buy rating in a research note on Tuesday, May 16th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the stock. The company has an average rating of Hold and an average price target of $4.00.

BioDelivery Sciences International (BDSI) opened at 3.50 on Monday. BioDelivery Sciences International has a 12 month low of $1.50 and a 12 month high of $3.60. The firm has a 50 day moving average of $2.77 and a 200-day moving average of $2.15. The firm’s market cap is $193.64 million.

BioDelivery Sciences International (NASDAQ:BDSI) last released its earnings results on Monday, May 15th. The specialty pharmaceutical company reported $0.58 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.09 by $0.49. BioDelivery Sciences International had a negative net margin of 0.19% and a negative return on equity of 1.45%. The company had revenue of $29.48 million during the quarter, compared to analysts’ expectations of $27.07 million. On average, equities research analysts forecast that BioDelivery Sciences International will post $0.14 earnings per share for the current year.

WARNING: “[[title]]” was first published by [[site]] and is the property of of [[site]]. If you are accessing this report on another website, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The correct version of this report can be accessed at [[permalink]].

Several hedge funds have recently made changes to their positions in the stock. GSA Capital Partners LLP bought a new stake in shares of BioDelivery Sciences International during the fourth quarter valued at approximately $142,000. Searle & CO. boosted its stake in shares of BioDelivery Sciences International by 27.1% in the fourth quarter. Searle & CO. now owns 234,100 shares of the specialty pharmaceutical company’s stock valued at $410,000 after buying an additional 49,850 shares during the period. Hikari Power Ltd bought a new stake in shares of BioDelivery Sciences International during the first quarter valued at approximately $503,000. Blair William & Co. IL boosted its stake in shares of BioDelivery Sciences International by 37.6% in the first quarter. Blair William & Co. IL now owns 693,181 shares of the specialty pharmaceutical company’s stock valued at $1,386,000 after buying an additional 189,484 shares during the period. Finally, Renaissance Technologies LLC bought a new stake in shares of BioDelivery Sciences International during the first quarter valued at approximately $290,000. Hedge funds and other institutional investors own 40.33% of the company’s stock.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.